大腸癌診断・治療の世界市場：2022-2028年

世界の大腸癌診断・治療の市場規模は予測期間中に4.3％のCAGRで成長すると予測されています。

肥満、アルコールやタバコの摂取、運動不足など、生活習慣の乱れによる大腸癌の有病率の上昇が同市場の成長を促す主な要因となっています。また、老年人口の増加とそれに伴う大腸癌の増加も市場成長の要因の一つです。さらに、医療費支出の継続的な改善、癌治療の技術的進歩、大腸癌の診断・治療に対する需要の高まりも新興国における市場を牽引すると予想されています。

当レポートでは、世界の大腸癌診断・治療の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 市場概要・洞察

第3章 競合情勢

• 主要企業分析
• 主要戦略分析
• COVID-19の主要企業への影響

第4章 市場決定要因

• 推進要因
• 抑制要因
• 機会

第5章 市場分析：区分別

• 世界の大腸癌診断・治療市場：タイプ別
  • 腺癌
  • カルチノイド腫瘍
  • リンパ腫
  • 肉腫
  • 消化管間質腫瘍（GISTS）
• 世界の大腸癌診断・治療市場：診断別
  • 直腸指診
  • 便潜血検査
  • S字結腸鏡検査
  • 大腸内視鏡検査
  • その他（生検）
• 世界の大腸癌診断・治療市場：治療別
  • 手術
  • 放射線療法
  • 化学療法
  • 標的療法
  • 免疫療法
• 世界の大腸癌診断・治療市場：エンドユーザー別
  • 総合病院
  • 癌研究センター

第6章 地域分析

• 北米
• 欧州
• アジア太平洋
• その他の地域

第7章 企業プロファイル

• Abbott Laboratories
• Bayer AG
• Beckman Coulter, Inc.
• Boehringer Ingelheim International GmbH
• Clinical Genomics Technologies Pvt. Ltd.
• EDP Biotech Corp.
• Epigenomics AG
• Eli Lilly and Co.
• Exact Sciences Corp.
• Genomictree Co., Ltd.
• IMV Inc.
• ISA Pharmaceuticals B.V.
• Merck & Co., Inc.
• Metabiomics Corp.
• Quest Diagnostics Inc.,
• Randox Laboratories Ltd
• F.Hoffmann-La Roche Ltd
• Siemens Healthcare Pvt. Ltd.
• Taiho Pharmaceutical Co., Ltd.
• VolitionRX Ltd.

LIST OF TABLES

• 1. GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
• 2. GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 3. GLOBAL ADENOCARCINOMAS COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 4. GLOBAL CARCINOID TUMORS COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 5. GLOBAL LYMPHOMAS COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 6. GLOBAL SARCOMAS COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 7. GLOBAL GASTROINTESTINAL STROMAL TUMORS (GISTS) COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 8. GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
• 9. GLOBAL SURGERY FOR COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 10. GLOBAL RADIATION THERAPY FOR COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 11. GLOBAL CHEMOTHERAPY FOR COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 12. GLOBAL TARGETED THERAPY FOR COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 13. GLOBAL IMMUNOTHERAPY FOR COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 14. GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
• 15. GLOBAL DIGITAL RECTAL EXAMINATION IN COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 16. GLOBAL FECAL OCCULT BLOOD TEST IN COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 17. GLOBAL FLEXIBLE SIGMOIDOSCOPY IN COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 18. GLOBAL COLONOSCOPY IN COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 19. GLOBAL OTHERS DIAGNOSIS IN COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 20. GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 21. GLOBAL MULTISPECIALTY HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 22. GLOBAL CANCER RESEARCH CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 23. NORTH AMERICAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 24. NORTH AMERICAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 25. NORTH AMERICAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
• 26. NORTH AMERICAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 27. NORTH AMERICAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
• 28. EUROPEAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 29. EUROPEAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 30. EUROPEAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
• 31. EUROPEAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
• 32. EUROPEAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 33. ASIA-PACIFIC COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 34. ASIA-PACIFIC COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 35. ASIA-PACIFIC COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
• 36. ASIA-PACIFIC COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 37. ASIA-PACIFIC COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
• 38. REST OF THE WORLD COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 39. REST OF THE WORLD COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 40. REST OF THE WORLD COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
• 41. REST OF THE WORLD COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 42. REST OF THE WORLD COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)

LIST OF FIGURES

• 1. IMPACT OF COVID-19 ON GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET, 2020-2027 ($ MILLION)
• 2. IMPACT OF COVID-19 ON GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY SEGMENT, 2020-2027 ($ MILLION)
• 3. RECOVERY OF GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET, 2021-2027 (%)
• 4. GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY TYPE, 2020 VS 2027 (%)
• 5. GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
• 6. GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY END-USER, 2020 VS 2027 (%)
• 7. GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
• 8. GLOBAL COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 9. GLOBAL ADENOCARCINOMAS COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027(%)
• 10. GLOBAL CARCINOID TUMORS COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 11. GLOBAL LYMPHOMAS COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 12. GLOBAL SARCOMAS COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 13. GLOBAL GASTROINTESTINAL STROMAL TUMORS (GISTS) COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 14. GLOBAL SURGERY IN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 15. GLOBAL RADIATION THERAPY IN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 16. GLOBAL CHEMOTHERAPY IN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 17. GLOBAL TARGETED THERAPY IN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 18. GLOBAL IMMUNOTHERAPY IN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 19. GLOBAL DIGITAL RECTAL EXAMINATION FOR COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 20. GLOBAL FECAL OCCULT BLOOD TEST FOR COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 21. GLOBAL FLEXIBLE SIGMOIDOSCOPY FOR COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 22. GLOBAL COLONOSCOPY FOR COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 23. GLOBAL OTHERS DIAGNOSIS FOR COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 24. GLOBAL MULTISPECIALTY HOSPITALS IN COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 25. GLOBAL CANCER RESEARCH CENTERS COLORECTAL CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
• 26. US COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 27. CANADA COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 28. UK COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 29. FRANCE COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 30. GERMANY COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 31. ITALY COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 32. SPAIN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 33. REST OF EUROPE COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 34. INDIA COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 35. CHINA COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 36. JAPAN COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 37. SOUTH KOREA COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 38. REST OF ASIA-PACIFIC COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
• 39. REST OF THE WORLD COLORECTAL CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)

Global Colorectal Cancer Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Type (Adenocarcinomas, Carcinoid Tumors, Lymphomas, Sarcomas, and Gastrointestinal Stromal Tumors (GISTS)), by Diagnosis (Digital Rectal Examination, Fecal Occult Blood Test, Flexible Sigmoidoscopy, Colonoscopy, and Others (Biopsy)), By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy), By End-User (Multispecialty Hospitals, and Cancer Research Centers), Forecast 2021-2027

The global colorectal cancer diagnosis and therapeutics market are anticipated to grow at a CAGR of 4.3% during the forecast period. Colorectal cancer therapeutics is a malignancy that begins in the colon or the rectum, and can likewise be named, colon tumors or rectal cancer depending upon where they begin. The rising prevalence of colorectal cancer due to poor lifestyles such as obesity, consumption of alcohol and tobacco, and lack of physical activity has been the major factor driving the market growth. Colorectal cancer is the fourth leading cause of cancer-related mortalities globally. As per the World Health Organization (WHO), in 2020, the number of deaths of males and females of all ages due to colorectal cancer was around 935,173 across the globe, which is 9.4% of total deaths. And the number of new colorectum cancer patients of both sexes of all ages in 2020 was around 1.9 million globally, which is 10% of new cancer cases. Additionally, as per the WHO, an increase of around 70% in colorectal cancer across the globe is expected by 2030.

Additionally, the increasing geriatric population and rising colorectal cancer associated with them is another factor driving the market growth. Moreover, the high prevalence of smokers and alcohol consumers who are most prone to this cancer has been boosting the market. For instance, as per the Centers for Disease Control and Prevention, in 2019, around 14 of every 100 US adults of age 18 years or above smoked cigarettes, which is 14% or 34.1 million adults. High cost of screening tests and treatment along with low awareness of this cancer act as major restraints for the market growth. However, ongoing improvements in healthcare expenditure, technological advancement for cancer treatment, and rising demand for colorectal cancer diagnosis and therapeutics are expected to drive the market in developing countries.

Impact of COVID-19 Pandemic on Global Colorectal Cancer Diagnosis and Treatment Market

The global colorectal cancer diagnosis and treatment market is hit by the outbreak of COVID-19 since December 2019. It has a sudden and dramatic impact on healthcare. Initially in Italy, screening for colorectal cancer (CRC) was forcefully suspended. The colorectal cancer diagnosis and therapies market has declined especially in the first half of 2020. The pandemic has had an impact on how people function and how different surgical procedures are performed. The number of cancer surgeries has significantly declined during the pandemic, due to the strict guidelines by the regulatory authorities to avoid all non-emergent surgeries. The outbreak of COVID-19 has disrupted the supply of raw materials and products across the globe.

As doctors frontline warriors fighting against COVID-19, all other treatment procedures were postponed except emergency cases. The COVID-19 pandemic shows severe symptoms in people, who are already suffering from chronic disease. This has impacted that people did not visit the hospital not to get exposed to the virus. To fight the pandemic the key players were focusing on the manufacturing of chemicals for sanitizers, and donated methylene diphenyl diisocyanate (MDI) to enable the manufacture of prefabricated polyurethane insulation panels for hospital construction and other materials to manufacture personal protective equipment (PPE) for medical personnel fighting the coronavirus. The market will witness "V" shape recovery in near future owing to the restart of key industries in major economies.

Segmental Outlook

The global colorectal cancer diagnosis and therapeutics market are segmented based on type, diagnosis, treatment, and end-user. Based on the type, the market is segmented into adenocarcinomas, carcinoid tumors, lymphomas, sarcomas, and gastrointestinal stromal tumors (GISTS). Based on the diagnosis, the market is segmented into digital rectal examination, fecal occult blood test, flexible sigmoidoscopy, colonoscopy, and others diagnoses. Based on the treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Apart from this, by end-users, the market is segmented into multispecialty hospitals and cancer research centers.

Global Colorectal Cancer Diagnosis and Therapeutics Market Share by Treatment, 2020 (%)

Global Colorectal Cancer Diagnosis and Therapeutics Market Share by Treatment

Surgery Segment holds the significant share in the Market

Among the treatment for colorectal cancer, the surgery segment held the highest share in 2020 and is also anticipated to grow during the forecast period. Surgery is used for early-stage cancers, and the type of surgery depends on the stage of cancer. It is a medical specialty that uses operative instruments on a person to treat a disease or injury, to improve bodily function, or to repair unwanted ruptured areas. Surgery is done for the removal of the tumor and some surrounding healthy tissue during an operation. This is known as surgical resection. Surgery is the most common and widely used treatment for colorectal cancer. During surgery, a part of the healthy colon or rectum and nearby lymph nodes to be removed. When the colon cancer is very small then minimally invasive surgery will be done such as removing polyps during a colonoscopy (polypectomy), endoscopic mucosal resection, and laparoscopic surgery. The factors such as rising quality assessment in hospitals, growing colorectal cancer cases among individuals, and increasing demand for minimal complication rates in surgery of special colorectal cancer are anticipating the market growth during the forecast period.

Regional Outlooks

The global colorectal cancer diagnosis and therapeutics market are further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others, and the Rest of the World (the Middle East and Africa, and Latin America). North America has been predicted to dominate the global colorectal cancer diagnosis and therapeutics market due to well-established health infrastructure, development in technology, support from the government, and high prevalence of this cancer towards people. For instance, as per the American Cancer Society, around 104,270 new cases of colon cancer and around 45,230 new cases of rectal cancer are expected in the US in 2021.

Global Colorectal Cancer Diagnosis and Therapeutics Market Growth, by Region 2021-2027

Global Colorectal Cancer Diagnosis and Therapeutics Market Growth, by Region

Asia-Pacific is projected to have a considerable growth in the global colorectal cancer diagnosis and therapeutics market

Asia-Pacific is anticipated to have a considerable growth in the global colorectal cancer diagnosis and therapeutics market. The rising geriatric population, increasing incidence and prevalence rate of colorectal cancer are the factors that are growing the market demand in the region. As per the report of WHO, in 2020, in the Asia-pacific region, around 569,186 incidences of colon cancer were recorded, which is 49.6% of total cases across the globe. The reason for more new cases of cancers and mortalities is having a huge population base in the region. Besides, around 296,236 mortalities were recorded due to colon cancer in 2020, which was around 51.4%.

Market Players Outlook

The key players of the colorectal cancer diagnosis and therapeutics market include Abbott Diagnostics, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Beckman Coulter, F.Hoffmann-La Roche Ltd, Quest Diagnostics Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2020, IMV Inc., an immunology company, announced the collaboration with The Wistar Institute. This collaboration was done for the development of a targeted T cell therapy against the BRAF cancer mutation, based on the peptides. This gene's mutations are the most common cancer-causing mutation in melanoma and have also been seen in colorectal cancer, thyroid cancer, and others.

The Report Covers

• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global colorectal cancer diagnosis and therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Colorectal Cancer Diagnosis and Therapeutics Industry
• Recovery Scenario of Global Colorectal Cancer Diagnosis and Therapeutics Industry
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. BY Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
  • 3.1.1. Overview
  • 3.1.2. Financial Analysis
  • 3.1.3. SWOT Analysis
• 3.2. Key Strategy Analysis
• 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global Colorectal Cancer Diagnosis and Therapeutics Market by Type
  • 5.1.1. Adenocarcinomas
  • 5.1.2. Carcinoid Tumors
  • 5.1.3. Lymphomas
  • 5.1.4. Sarcomas
  • 5.1.5. Gastrointestinal Stromal Tumors (GISTS)
• 5.2. Global Colorectal Cancer Diagnosis and Therapeutics Market by Diagnosis
  • 5.2.1. Digital Rectal Examination
  • 5.2.2. Fecal Occult Blood Test
  • 5.2.3. Flexible Sigmoidoscopy
  • 5.2.4. Colonoscopy
  • 5.2.5. Others (Biopsy)
• 5.3. Global Colorectal Cancer Diagnosis and Therapeutics Market by Treatment
  • 5.3.1. Surgery
  • 5.3.2. Radiation Therapy
  • 5.3.3. Chemotherapy
  • 5.3.4. Targeted Therapy
  • 5.3.5. Immunotherapy
• 5.4. Global Colorectal Cancer Diagnosis and Therapeutics Market by End-User
  • 5.4.1. Multispecialty Hospitals
  • 5.4.2. Cancer Research Centers

6. Regional Analysis

• 6.1. North America
  • 6.1.1. United States
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. South Korea
  • 6.3.5. Rest of Asia-Pacific
• 6.4. Rest of the World

7. Company Profiles

• 7.1. Abbott Laboratories
• 7.2. Bayer AG
• 7.3. Beckman Coulter, Inc.
• 7.4. Boehringer Ingelheim International GmbH
• 7.5. Clinical Genomics Technologies Pvt. Ltd.
• 7.6. EDP Biotech Corp.
• 7.7. Epigenomics AG
• 7.8. Eli Lilly and Co.
• 7.9. Exact Sciences Corp.
• 7.10. Genomictree Co., Ltd.
• 7.11. IMV Inc.
• 7.12. ISA Pharmaceuticals B.V.
• 7.13. Merck & Co., Inc.
• 7.14. Metabiomics Corp.
• 7.15. Quest Diagnostics Inc.,
• 7.16. Randox Laboratories Ltd
• 7.17. F.Hoffmann-La Roche Ltd
• 7.18. Siemens Healthcare Pvt. Ltd.
• 7.19. Taiho Pharmaceutical Co., Ltd.
• 7.20. VolitionRX Ltd.